THE USEFULNESS OF AN ARTERIOVENOUS SHUNT COMBINED WITH A BETA MICROPROBE FOR THE MEASUREMENT OF INPUT FUNCTION IN RATS

in Journal of Labelled Compounds & Radiopharmaceuticals (2009, July), 52(S1), 106

TIME-DEPENDENT PREFERENTIAL IN VIVO D2 OCCUPANCY BY AMISULPRIDE IN THE MEDIAL STRIATUM – CONTINUOUS MEASUREMENT USING A BETA MICROPROBE SYSTEM

in Journal of Labelled Compounds & Radiopharmaceuticals (2009, July), 52(S1), 105

Tertiary Alcohols to Avoid Evaporation in Fluorine-18 Labeling

in Journal of Labelled Compounds & Radiopharmaceuticals (2009, July), 52(S1), 204

Use of Organic Bases for 18F-Fluoride Anion Exchange Elution avoiding the Classical Azeotropic drying Step Before Labeling

in Journal of Labelled Compounds & Radiopharmaceuticals (2009, July), 52(S1), 198

Large Scale Preparation of [18]Fluoromethoxybenzyl Bromides, Key Precursors for 2-[18F]Fluoro-L-Tyrosine and 6-[18F]Fluoro-L-Dopa

in Journal of Labelled Compounds & Radiopharmaceuticals (2009, July), 52(S1), 292

Synthesis, quality control and in vivo evaluation of [I-123] rhTIMP-2, a potential tumour-imaging agent

in Journal of Labelled Compounds & Radiopharmaceuticals (2005), 48(5), 387-396

Matrix metalloproteinases (MMPs) are enzymes involved in the turnover of the extracellular matrix. Their overexpression in tumours may provide a target for diagnostic imaging by using labelled MMP ... [more ▼]

Matrix metalloproteinases (MMPs) are enzymes involved in the turnover of the extracellular matrix. Their overexpression in tumours may provide a target for diagnostic imaging by using labelled MMP inhibitors. MMPs are inhibited by endogenous tissue inhibitors of metalloproteinases (TIMPs). The enhanced production of MT1-MMP, located on the surface of cells within or in the direct vicinity of the tumour, and the high affinity interaction between TIMP-2 and MT1-MMP suggested that TIMP-2 could be a potential agent for non-invasive monitoring of cancer MMP levels, diagnosis of primary and secondary tumours and tumour response to MMP inhibitor therapy. There is also evidence that I-125-rhTIMP-2 internalizes, which is an important feature for its possible use as a radiotherapeuticum if labelled with I-131. Labelling of rhTIMP-2 was performed using the iodogen method resulting in a radiochemical yield of 51.1 +/- 11.8% (n = 5) and a radiochemical purity of > 98%. The trichloroacetic acid (TCA) precipitability of I-123 rhTIMP-2 was 95.2%. SDS-PAGE confirmed the correct size (21 kDa) of the purified I-123 rhTIMP-2 without degradation. HPLC showed one radioactive peak with a retention time corresponding to the nonlabelled rhTIMP-2. In vivo biodistribution showed no long-term accumulation in organs and the possibility to accumulate in the tumour. These results show the potential of I-123 rhTIMP-2 as tumour-imaging agent. Copyright (c) 2005 John Wiley [less ▲]

Ex Vivo Evaluation of p-[18F]D-MPPF for the Study of 5-HT1A Receptors.

in Journal of Labelled Compounds & Radiopharmaceuticals (2005), 48

Radiochemical Synthesis of p-[18F]Desmethyl-MPPF (p-[18F]D-MPPF) for the Study of 5-HT1A Receptors

in Journal of Labelled Compounds & Radiopharmaceuticals (2003, August), 46(S1), 157

Simple device for the radiosynthesis of [carbonyl-11C]amides, esters and ketones using carbon-11 monoxide.

in Journal of Labelled Compounds & Radiopharmaceuticals (2003), 46

Radiosynthesis of 7-[18F]fluoroindole derivatives.

in Journal of Labelled Compounds & Radiopharmaceuticals (2003), 46